Hubei Hongyuan Pharmaceutical Technology Co., Ltd.

This study investigated the pharmacokinetics of the test formulation, Ailamod tablets (25 mg; manufactured by Hubei Tongdetang Pharmaceutical Co., Ltd.), and the reference formulation, Ailamod tablets (Aidexin®, 25 mg; manufactured by Hainan Xiansheng Pharmaceutical Co., Ltd.), administered orally in a single dose under fasting and postprandial conditions in healthy adult participants, and evaluated the bioequivalence of the two formulations under fasting and postprandial conditions.

Primary Study Objective: This study used dapagliflozin tablets (licensed by Hubei Hongyuan Pharmaceutical Technology Co., Ltd.) as the test formulation and dapagliflozin tablets (trade name: Andatang) (licensed by AstraZeneca AB) as the reference formulation to conduct a human bioequivalence study under fasting and postprandial conditions to evaluate the bioequivalence of the test and reference formulations in healthy study participants. Secondary Study Objective: To observe the safety of the test and reference formulations in healthy study participants.

Primary study objective: To study the pharmacokinetics of a single oral dose of the test preparation tadalafil tablets (20 mg, produced by Hubei Tongdetang Pharmaceutical Co., Ltd.) and the reference preparation tadalafil tablets (Cialis®, 20 mg, produced by Lilly del Caribe, Inc.) in healthy participants in the fasting and fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. Secondary study objective: To evaluate the safety of the test preparation tadalafil tablets (20 mg) and the reference preparation tadalafil tablets (Cialis®, 20 mg) in healthy participants.